109. 非典型溶血性尿毒症症候群 Atypical hemolytic uremic syndrome Clinical trials / Disease details

臨床試験数 : 115 / 薬物数 : 37 - (DrugBank : 7) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 10

2 trials found

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02464891 (ClinicalTrials.gov)	June 4, 2015	26/5/2015	Complement Inhibition in aHUS Dialysis Patients	An Open-label Phase 2 Study to Assess the Effect of C5aR Antagonist Therapy by CCX168Oral Administra ...	Atypical Hemolytic Uremic Syndrome	Drug: CCX168	Mario Negri Institute for Pharmacological Research	ChemoCentryx	Terminated	18 Years	N/A	All	6	Phase 2	Italy
2	EUCTR2014-004261-24-IT (EUCTR)	08/05/2015	25/09/2018	PROPOSAL OF STUDY TO DETERMINE IF THE ORAL ADMINISTRATION OF CCX168INHIBITS THE ACTIVITY 'COMPLEMENT ...	AN OPEN-LABEL PHASE 2 STUDY TO ASSESS THE EFFECT OF C5AR ANTAGONIST THERAPY BY CCX168ORAL ADMINISTRA ...	Atypical Hemolytic Uremic Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10019515;Term ...	Product Name: CCX168 Product Code: CCX168	IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI	NULL	Not Recruiting			Female: yes Male: yes	10	Phase 2	Italy

First Previous1Next Last